Literature DB >> 10639168

Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization.

H Wang1, M N Griffiths, D R Burton, P Ghazal.   

Abstract

We have compared the kinetics of antibody responses in conventional and dendritic cell-targeted immunization by using a model antigen in mice. Targeting was achieved by linking the reporter antigen (polyclonal goat anti-hamster antibody) to N418, a hamster mAb that binds to the CD11c molecule on the surface of murine dendritic cells. Intradermal injection of submicrogram quantities of goat anti-hamster antibody complexed to mAb N418 elicited goat antibody-specific serum IgG in mice. Antigen-specific IgG titers were detectable by day 5, with titers that ranged from 1:1000 to 1:100,000 by day 7. In contrast, when the goat antigen was injected alone or in the presence of a hamster antibody control to form nontargeted complexes, goat-specific serum IgG was undetectable at day 7. Additional control experiments showed that the interaction between the model antigen and mAb N418 is required for amplification of the serum antibody response. These studies demonstrate that a single-step, facilitated-delivery of small amounts of protein antigen to dendritic cells in vivo can give very rapid and high antibody responses. The approach may be particularly useful for vaccination immediately before or just after exposure to a pathogen and may enhance the utility of subunit antigens as immunogens.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10639168      PMCID: PMC15419          DOI: 10.1073/pnas.97.2.847

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

1.  Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes.

Authors:  L Zitvogel; A Regnault; A Lozier; J Wolfers; C Flament; D Tenza; P Ricciardi-Castagnoli; G Raposo; S Amigorena
Journal:  Nat Med       Date:  1998-05       Impact factor: 53.440

2.  CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer.

Authors:  L Höltl; C Rieser; C Papesh; R Ramoner; G Bartsch; M Thurnher
Journal:  Lancet       Date:  1998-10-24       Impact factor: 79.321

3.  Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA.

Authors:  S K Nair; D Boczkowski; M Morse; R I Cumming; H K Lyerly; E Gilboa
Journal:  Nat Biotechnol       Date:  1998-04       Impact factor: 54.908

Review 4.  The immunotargeting approach to adjuvant-independent subunit vaccine design.

Authors:  B H Barber
Journal:  Semin Immunol       Date:  1997-10       Impact factor: 11.130

5.  Six decades of vaccine development--a personal history.

Authors:  M R Hilleman
Journal:  Nat Med       Date:  1998-05       Impact factor: 53.440

6.  Why do we not have an HIV vaccine and how can we make one? .

Authors:  D R Burton; J P Moore
Journal:  Nat Med       Date:  1998-05       Impact factor: 53.440

Review 7.  Dendritic cells in the T-cell areas of lymphoid organs.

Authors:  R M Steinman; M Pack; K Inaba
Journal:  Immunol Rev       Date:  1997-04       Impact factor: 12.988

8.  Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice.

Authors:  Y Shimizu; L G Guidotti; P Fowler; F V Chisari
Journal:  J Immunol       Date:  1998-11-01       Impact factor: 5.422

9.  Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo.

Authors:  R C Fields; K Shimizu; J J Mulé
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

Review 10.  Progress in the development of an HIV-1 vaccine.

Authors:  N L Letvin
Journal:  Science       Date:  1998-06-19       Impact factor: 47.728

View more
  26 in total

Review 1.  In vivo maturation and migration of dendritic cells.

Authors:  L Flores-Romo
Journal:  Immunology       Date:  2001-03       Impact factor: 7.397

2.  A fusion DNA vaccine that targets antigen-presenting cells increases protection from viral challenge.

Authors:  G Deliyannis; J S Boyle; J L Brady; L E Brown; A M Lew
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

3.  Dendritic cell targeted vaccines: Recent progresses and challenges.

Authors:  Pengfei Chen; Xinsheng Liu; Yuefeng Sun; Peng Zhou; Yonglu Wang; Yongguang Zhang
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

4.  Ligation of CD11c during vaccination promotes germinal centre induction and robust humoral responses without adjuvant.

Authors:  Ann L White; Alison L Tutt; Sonya James; Kevin A Wilkinson; Fernanda V V Castro; Sandra V Dixon; Jessica Hitchcock; Mahmood Khan; Aymen Al-Shamkhani; Adam F Cunningham; Martin J Glennie
Journal:  Immunology       Date:  2010-05-10       Impact factor: 7.397

5.  Biochemical, pathological and oncological relevance of Gb3Cer receptor.

Authors:  D Đevenica; V Čikeš Čulić; A Vuica; A Markotić
Journal:  Med Oncol       Date:  2010-11-11       Impact factor: 3.064

6.  The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement.

Authors:  Irina Caminschi; Anna I Proietto; Fatma Ahmet; Susie Kitsoulis; Joo Shin Teh; Jennifer C Y Lo; Alexandra Rizzitelli; Li Wu; David Vremec; Serani L H van Dommelen; Ian K Campbell; Eugene Maraskovsky; Hal Braley; Gayle M Davey; Patricia Mottram; Nicholas van de Velde; Kent Jensen; Andrew M Lew; Mark D Wright; William R Heath; Ken Shortman; Mireille H Lahoud
Journal:  Blood       Date:  2008-07-30       Impact factor: 22.113

7.  Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax.

Authors:  Mark T Albrecht; Han Li; E Diane Williamson; Chris S LeButt; Helen C Flick-Smith; Conrad P Quinn; Hans Westra; Darrell Galloway; Alfred Mateczun; Stanley Goldman; Herman Groen; Les W J Baillie
Journal:  Infect Immun       Date:  2007-07-23       Impact factor: 3.441

8.  Bone marrow dendritic cell-mediated regulation of TLR and B cell receptor signaling in B cells.

Authors:  Vishal J Sindhava; Halide Tuna; Beth W Gachuki; David J DiLillo; Margarita G Avdiushko; Thandi M Onami; Thomas F Tedder; Donald A Cohen; Subbarao Bondada
Journal:  J Immunol       Date:  2012-08-31       Impact factor: 5.422

9.  Carbohydrate-mediated targeting of antigen to dendritic cells leads to enhanced presentation of antigen to T cells.

Authors:  Eddie W Adams; Daniel M Ratner; Peter H Seeberger; Nir Hacohen
Journal:  Chembiochem       Date:  2008-01-25       Impact factor: 3.164

10.  Targeting Dendritic Cells in vivo for Cancer Therapy.

Authors:  Irina Caminschi; Eugene Maraskovsky; William Ross Heath
Journal:  Front Immunol       Date:  2012-02-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.